Research Article
Efficacy of Perampanel in Nocturnal Seizures in Adult Patients with Epilepsy
Table 1
Demographic and clinical baseline characteristics.
| Variable | |
| Age, years ( (range)) | (16-77) | Sex (male), (%) | 29 (60.4) | Age at epilepsy onset, years ( (range)) | (0-77) | Epilepsy duration, years ( (range)) | (0.5-63) | Epilepsy type, (%) | | Focal | 39 (81.3) | Generalized | 6 (12.5) | Focal/generalized | 1 (2.1) | Unknown | 2 (4.2) | Focal localization (), (%) | | Frontal | 12 (30.8) | Occipital | 1 (2.6) | Temporal | 25 (64.1) | Undetermined | 1 (2.6) | Syndrome, (%) | | Focal epilepsy of unknown etiology | 14 (29.2) | Focal epilepsy of structural etiology | 29 (60.4) | Idiopathic generalized epilepsy | 3 (6.3) | Juvenile myoclonic epilepsy | 1 (2.1) | Other | 1 (2.1) | Etiology, (%) | | Unknown | 14 (29.2) | Structural | 27 (56.3) | Infectious | 2 (4.2) | Genetics | 5 (10.4) | Specific cause (), (%) | | Vascular | 3 (11.1) | Tumor | 5 (18.5) | Mesial sclerosis | 8 (29.6) | Malformation cortical development | 8 (29.6) | Cavernoma/arteriovenous malformation | 1 (3.7) | Postanoxic encephalopathy after cardiac arrest | 1 (3.7) | Neonatal anoxia | 1 (3.7) | Drug-resistant epilepsy, (%) | 37 (70.8) |
|
|
CNS: central nervous system; SD: standard deviation.
|